<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Re: Fascelli et al: Combined biparametric prostate magnetic resonance ımaging and prostate-specific antigen in the detection of prostate cancer: A validation study in a biopsy-naive patient population (urology 2016; 88:125-134)

Thumbnail Image

Files

Sertkaya-Zulfu 2016.pdf (77.78 KB)

Date

2016

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier Science Inc

Access Rights

info:eu-repo/semantics/openAccess

DOI

10.1016/j.urology.2016.04.011

Abstract

I read with interest the article by Fascelli et al1The authorsaimed to validate the use of biparametric (T2- and diffusion-weighted) magnetic resonance imaging and prostate-specific antigen (PSA) or PSA density in a biopsy-naivecohort at risk for prostate cancer (PCa) and they used for-mulas for validation.

Description

WOS: 000383698300057
PubMed ID: 27112511

Keywords

Mortality , Biparametric , Prostate

Journal or Series

Urology

WoS Q Value

Q3

Scopus Q Value

Q1

Volume

95

Issue

Citation

Sertkaya, Z. (2016). Re: Fascelli et al: Combined biparametric prostate magnetic resonance ımaging and prostate-specific antigen in the detection of prostate cancer: A validation study in a biopsy-naive patient population (urology 2016; 88:125-134). Urology, 95, 223-223. https://dx.doi.org/10.1016/j.urology.2016.04.011.

URI

https://dx.doi.org/10.1016/j.urology.2016.04.011
 https://hdl.handle.net/20.500.12511/4048

Collections

Scopus İndeksli Yayınlar Koleksiyonu
Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu

Endorsement

Review

Supplemented By

Referenced By

Rights and licensing

info:eu-repo/semantics/openAccess